Jump to content

Foravirumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Natureium (talk | contribs) at 05:50, 18 December 2016 (added Category:Experimental drugs using HotCat). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Foravirumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
Targetrabies virus glycoprotein
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
ChEMBL
Chemical and physical data
FormulaC6400H9914N1718O1998S44
Molar mass144.3 kg/mol g·mol−1
 ☒NcheckY (what is this?)  (verify)

Foravirumab is a monoclonal antibody for the prophylaxis of rabies.[1] It is under development by Sanofi/Crucell.[2]

References

  1. ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
  2. ^ Khardori, Nancy Misri (2011). Biologic Response Modifiers in Infectious Diseases, An Issue of Infectious Disease Clinics. London: Elsevier Health Sciences. p. 158. ISBN 9781455712076.


Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Foravirumab&oldid=755469332"